CJC-1295

1. What is it?

CJC-1295 was developed as a modified counterpart of a GHRH fragment, the natural signal that stimulates the pituitary gland to release growth hormone. The original molecule included DAC, a component enabling lasting attachment to albumin, one of the main blood proteins. In this profile, CJC-1295 refers to that version. If a description does not specify DAC, it is unsafe to assume that it means the substance used in the historical clinical study. [85] [86]

2. Why do people turn to it?

Interest in CJC-1295 mainly concerns muscle, fat reduction and recovery. Expectations come from its action on growth hormone and the long-lasting effect of the DAC version. Duration of action alone, however, does not tell us whether any of these goals was achieved or whether the benefits outweigh the risks. [83] [86]

CJC-1295 was developed to stimulate the body's own GH release for longer. Uses related to GH deficiency were considered, but the first published trials involved healthy adults. This matters: establishing whether a molecule raises hormone levels in volunteers comes before showing patient benefits. The documentation does not establish approved treatment of obesity, fatigue or sports injuries with this peptide, although these uses appear in advertisements. [83] [86]

3. How does it work?

Albumin acts here as a protein to which the peptide binds after administration. This slows its disappearance from the blood and prolongs stimulation of the hormone system. Studies found increases in GH and IGF-1, a factor involved in growth hormone's effects on tissues. A separate experiment found that periodic GH pulses were preserved, although concentrations between pulses also increased. This does not mean the whole hormone system remains unchanged or works more naturally. [85] [84]

4. What do studies actually show?

A 2006 publication described two short studies in healthy adults lasting 28 and 49 days. They mainly assessed hormone concentrations, how long the substance remained in the body and tolerability. Another study from the same year measured overnight GH secretion in healthy men in detail. The results confirm hormonal activity of the albumin-binding version. They did not measure longer life or successful treatment of injuries, and an increase in IGF-1 alone does not replace those outcomes. [83] [84]

5. What do we still not know?

The main limitations are short follow-up, a selected population of healthy participants and a focus on laboratory markers. These do not establish the balance of benefits and harms during long-term use. The FDA also identified uncertainty about the chemical form used in some reports and distinguished several forms of CJC. Even a genuine paper may therefore be an unsuitable source for a different variant. It is particularly misleading to attribute DAC's effects lasting several days to a peptide from which that component has been removed. [86] [83]

6. What are the risks?

Available studies and FDA documents describe injection-site reactions, headaches, nausea and reactions associated with widened blood vessels. Short-term tolerability does not establish the risk of months of GH and IGF-1 stimulation. Substance quality is a separate issue: FDA noted incomplete impurity and molecule-clustering data. Confusing DAC and non-DAC forms also matters because their durations of action differ. [86]

In sport governed by WADA anti-doping rules, this substance is prohibited at all times, including outside competition. The 2026 list names it explicitly. Use during training or a break between competitions is also covered by the ban. [108]

7. Is it an approved medicine?

In the FDA's December 2024 assessment, the CJC-1295 forms discussed were not ingredients in an approved medicinal product. They were assessed under US compounding rules. Inclusion in such a document does not authorize a treatment, and a chemical identifier entry is not drug approval. This concerns the USA, not Polish authorization or an approved indication for improving performance. [86]

8. What is new in research?

A paper on detecting CJC-1295 in horse plasma using an ELISA test was published on 14 October 2026. It concerned the DAC version and its complexes with blood proteins, and supported testing for prohibited use in racing. It is a real new publication, but not new confirmation of health benefits in humans. A review of sources up to 3 November 2026 found no new large clinical trial that would justify rejuvenation claims for this substance. [88] [86]

Where does this information come from?

References link to the publications and documents used. Each source includes its material type and what was reviewed; findings concern the substance, form and study population described.